Hutchison China MediTechのSMA 50
Hutchison China MediTechのSMA 50は何ですか。
Hutchison China MediTech Ltd.のSMA 50はGBX288 -13.19%です。
SMA 50の定義は何ですか。
SMA 50は、過去50日間の終値の非加重平均として計算された過去50日間の平均株価である。
Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
LSEのセクタHealth CareにおけるSMA 50の企業と比べるHutchison China MediTech
Hutchison China MediTechは何をしますか。
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Hutchison China MediTechと類似のsma 50
- R. S. Software (India)のSMA 50は₨287 -0.51%です。
- Dunedin Income Growth Investment Trust PlcのSMA 50はGBX287 -1.26%です。
- Essex Property TrustのSMA 50は$287 +6.94%です。
- RBC BearingsのSMA 50は$287 -1.07%です。
- River City BankのSMA 50は$287 +4.22%です。
- Linc Pen & PlasticsのSMA 50は₨287 -22.28%です。
- Hutchison China MediTechのSMA 50はGBX288 -13.19%です。
- Gujarat Apollo IndustriesのSMA 50は₨288 +25.26%です。
- Aspinwall andのSMA 50は₨288 +3.96%です。
- CoastalのSMA 50は₨288 -10.21%です。
- R. S. Software (India)のSMA 50は₨288 +0.23%です。
- SaksoftのSMA 50は₨289 +16.41%です。
- RelianceのSMA 50は$289 -6.31%です。